MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Precipio Interest Expense 2011-2026 | PRPO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 839 K | -74 K | - | - | - | - | - | - | - | -1 K | -14 K | - | 60 K | 11 K | 259 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 839 K | -74 K | 154 K |
Quarterly Interest Expense Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18 K | 898 K | - | - | -29 K | -11 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 268 K | -648 K | - | - | -2.65 M | -2.88 M | - | - | - | - | - | - | -6 K | - | -13 K | - | -1 K | - | - | - | 1 K | - | 53 K | - | -6 K | 8 K | 20 K | - | -2 K | 1 K | 231 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 898 K | -2.88 M | -252 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.62 | -2.12 % | $ 2.15 M |  USA |
 |
Agilent Technologies
A
|
81 M | $ 115.05 | -0.49 % | $ 35 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.54 | -1.76 % | $ 682 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Illumina
ILMN
|
-292 M | $ 126.49 | -1.58 % | $ 20.1 B | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 22.26 | 1.88 % | $ 1.19 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 83.21 | -1.08 % | $ 5.62 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 15.15 | -2.88 % | $ 458 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 165.64 | -3.26 % | $ 8.21 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 16.89 | -1.29 % | $ 378 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 82.71 | -6.54 % | $ 10.4 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 27.06 | -1.74 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
24 K | $ 5.44 | -8.72 % | $ 322 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 1.93 | - | $ 8.54 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 7.15 | -1.72 % | $ 298 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 413.83 | -1.79 % | $ 11.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Biomerica
BMRA
|
367 | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 469.78 | 0.37 % | $ 177 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 100.97 | -2.18 % | $ 8.33 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 260.26 | -1.2 % | $ 21.7 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.61 | -5.24 % | $ 61.9 M | Irlanda |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.2 | -2.54 % | $ 2 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 120.4 | -4.21 % | $ 5.63 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 59.76 | -2.03 % | $ 3.57 B | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.86 | 2.85 % | $ 1.13 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.87 | 0.72 % | $ 451 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 201.83 | -1.25 % | $ 19.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 195.01 | -0.82 % | $ 21.6 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |